Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make breast cancer progress, and Keytruda gets under your skin.

Behind the Headlines Episode 26: Clinical Advances, Weight-Loss Deals, and Swiss Startup Strength

Articles

This article takes a look at the developing use of AI in pharmaceutical development and manufacturing.

How AI is Accelerating Pharmaceutical Development

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The go-ahead for Novartis’ oral treatment marks a new option for patients with spontaneous urticaria who remain symptomatic despite antihistamine therapy.

What FDA’s Remibrutinib Approval Reveals About the Future of BTK Inhibitors

This review of the nitrosamines contamination problem in pharmaceuticals takes a look at how the crisis started and developed.

The Story of Nitrosamines

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower prescription drug prices in the United States.

Pfizer Reaches First Agreement with White House on MFN Pricing; Who Will Be Next?

A draft reflection paper on patient experience data is up for public consultation until Jan. 31, 2026.

EMA Looks to Include Patient Perspectives in Drug Regulation

FDA's Center for Biologics Evaluation and Research has released updated draft recommendations for sponsors of cell therapies, gene therapies, and tissue products.

How FDA's New RMAT Guidance Impacts Clinical, CMC Strategies

 is vice-president, Product Management for AI & Data at 

, based in London. A data science actuary, he has built his career in fintech and health-tech, and specializes in AI-powered, data-driven, yet human-centric product innovation. He previously led an AstraZeneca digital incubator and today remains on the board of a health charity, Scleroderma & Raynaud's UK (SRUK), which is dedicated to improving the lives of people affected by those conditions in the UK.

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Two: Agentic AI’s Adoption in Life Sciences

Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, to learn more about Crown Bioscience’s collaboration with Medicines Discovery Catapult on a new development platform for radiopharmaceuticals.

Radiopharmaceuticals: A Development Platform

Your weekly news hub for biopharma trends, FDA regulations, M&A deals, supply chain insights, drug development innovations from BIO-Europe, and more.

News